Track Enliven Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Enliven Therapeutics Inc. Common Stock ELVN · Stock Open Enliven Therapeutics Inc. Common Stock in new tab

48.80 USD
EPS
-1.69
P/B
4.29
ROE
-16.77
Beta
0.36
Target Price
74.33 USD
Loading chart...
Key Metrics
Earnings dateMarch 2, 2027
EPS-1.69
Book Value11.92
Price to Book4.29
Debt/Equity0.15
% Insiders6.194%
Estimates
Forward P/E-25.72
Forward EPS-1.99
Target Mean Price74.33

DCF valuation

Model fair value for Enliven Therapeutics Inc. Common Stock (ELVN)
Result
Sign in to run the valuation for ELVN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Strong buy · mean target 74.33 USD (low 69.00, high 82.00) · as of 12 Nov 2026
Low 69.00
Mean 74.33
High 82.00
Price 48.80
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Enliven Therapeutics Inc. Common Stock Logo Enliven Therapeutics Inc. Common Stock Analysis (ELVN)

United States Health Care Official Website Stock

Is Enliven Therapeutics Inc. Common Stock a good investment? Enliven Therapeutics Inc. Common Stock (ELVN) is currently trading at 48.80 USD. Market analysts have a consensus price target of 74.33 USD. This suggests a potential upside from current levels.

Earnings Schedule: Enliven Therapeutics Inc. Common Stock is expected to release its next earnings report on March 2, 2027. The market consensus estimate for Forward EPS is -1.99.

Investor FAQ

Does Enliven Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Enliven Therapeutics Inc. Common Stock?

Enliven Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 2, 2027. The company currently has a trailing EPS of -1.69.

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.

Exchange Ticker
NMS (United States) ELVN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Feb. 24, 2023 1:4
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion